Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + modified FOLFIRINOX
- Development stage
- Unknown
- Lead developer
- Yonsei University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy regimen, being evaluated by Yonsei University, consists of the angiogenesis inhibitor bevacizumab (Avastin) and a modified FOLFIRINOX chemotherapy backbone (oxaliplatin, irinotecan, leucovorin, and 5-fluorouracil). It is specifically designed to treat rare mucinous gynecologic cancers, including mucinous ovarian, fallopian tube, and primary peritoneal carcinomas, which typically exhibit poor responses to standard platinum-based treatments. Bevacizumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor-A (VEGF-A), while the FOLFIRINOX components provide multi-targeted cytotoxic activity similar to regimens used in gastrointestinal malignancies.
- Brand names
- Avastin
- Other names
- Bevacizumab plus modified FOLFIRINOXmFOLFIRINOX + bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + modified FOLFIRINOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + modified FOLFIRINOX.